Literature DB >> 18515440

Ethical issues related to BRCA gene testing in orthodox Jewish women.

Pnina Mor1, Kathleen Oberle.   

Abstract

Persons exhibiting mutations in two tumor suppressor genes, BRCA1 and BRCA2, have a greatly increased risk of developing breast and/or ovarian cancer. The incidence of BRCA gene mutation is very high in Ashkenazi Jewish women of European descent, and many issues can arise, particularly for observant Orthodox women, because of their genetic status. Their obligations under the Jewish code of ethics, referred to as Jewish law, with respect to the acceptability of various risk-reducing strategies, may be poorly understood. In this article the moral direction that Jewish law gives to women regarding testing, confidentiality, and other issues is explored. The intent is to broaden nurses' knowledge of how a particular religious tradition could impact on decision making around genetics testing, with the aim of enhancing their understanding of culturally sensitive ethical care.

Entities:  

Mesh:

Year:  2008        PMID: 18515440     DOI: 10.1177/09697330080150041201

Source DB:  PubMed          Journal:  Nurs Ethics        ISSN: 0969-7330            Impact factor:   2.874


  8 in total

1.  Integrating genetic and genomic information into effective cancer care in diverse populations.

Authors:  L Fashoyin-Aje; K Sanghavi; K Bjornard; J Bodurtha
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

2.  The doctor is just a messenger: beliefs of ultraorthodox Jewish women in regard to breast cancer and screening.

Authors:  Anat Freund; Miri Cohen; Faisal Azaiza
Journal:  J Relig Health       Date:  2014-08

3.  Barriers to cancer screening among Orthodox Jewish women.

Authors:  Rifky Tkatch; Janella Hudson; Anne Katz; Lisa Berry-Bobovski; Jennifer Vichich; Susan Eggly; Louis A Penner; Terrance L Albrecht
Journal:  J Community Health       Date:  2014-12

4.  Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.

Authors:  Brian S Finkelman; Wendy S Rubinstein; Sue Friedman; Tara M Friebel; Shera Dubitsky; Niecee Singer Schonberger; Rochelle Shoretz; Christian F Singer; Joanne L Blum; Nadine Tung; Olufunmilayo I Olopade; Jeffrey N Weitzel; Henry T Lynch; Carrie Snyder; Judy E Garber; Joellen Schildkraut; Mary B Daly; Claudine Isaacs; Gabrielle Pichert; Susan L Neuhausen; Fergus J Couch; Laura van't Veer; Rosalind Eeles; Elizabeth Bancroft; D Gareth Evans; Patricia A Ganz; Gail E Tomlinson; Steven A Narod; Ellen Matloff; Susan Domchek; Timothy R Rebbeck
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544

5.  Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach.

Authors:  Meghna S Trivedi; Hilary Colbeth; Haeseung Yi; Alejandro Vanegas; Rebecca Starck; Wendy K Chung; Paul S Appelbaum; Rita Kukafka; Isaac Schechter; Katherine D Crew
Journal:  Public Health Genomics       Date:  2019-06-04       Impact factor: 2.000

6.  Breast cancer incidence rates among orthodox Jewish women.

Authors:  Rifky Tkatch; Kendra Schwartz; Ronald D Shore; Louis A Penner; Michael S Simon; Terrance L Albrecht
Journal:  J Immigr Minor Health       Date:  2014-10

7.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

Review 8.  Phase changes in the BRCA policy domain.

Authors:  Stephen M Modell; Susan B King; Toby Citrin; Sharon L R Kardia
Journal:  J Relig Health       Date:  2014-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.